FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613767797> ?p ?o ?g. }

• W2613767797 endingPage "1660" @default.
• W2613767797 startingPage "1651" @default.
• W2613767797 abstract "To evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization (CNV) secondary to pseudoxanthoma elasticum (PXE) in a real-world setting.A descriptive, observational, multicenter study in a retrospective and prospective cohort was conducted in France that included patients who had received at least one injection of ranibizumab 0.5 mg during the period October 2011 to October 2014, for CNV secondary to PXE. Eligible patients were identified by review of medical records or during routine consultations. The main objectives were to describe patient characteristics, assess changes in best-corrected visual acuity [VA, Early Treatment Diabetic Retinopathy Study (ETDRS) letters] over time, the number and reasons for ranibizumab treatment and overall safety.Of the 72 enrolled patients (98 eyes) from 23 centers, 39 (54.2%) were male and mean [±standard deviation (SD)] age was 59.6 (±8.3) years. The mean VA was 64.6 letters at the first ranibizumab injection, which was maintained at the 1-year follow-up (64.7 letters). Thereafter, the mean VA was stable until the 4-year follow-up. At 4 years, the proportion of eyes with VA gain of ≥15 letters was 3/19 (15.8%) and stable VA (change between -15 and +15 letters) was 10/19 (52.6%). Mean (±SD) annual number of ranibizumab injections was 4.1 (±4.0), lower in the second versus first year. The most common reason for ranibizumab treatment was progression of neovascular activity (42.9%). No deaths or new safety findings were reported.In patients with CNV secondary to PXE, ranibizumab 0.5 mg resulted in stable VA over 4 years with a limited number of injections. Safety findings were consistent with the established safety profile of ranibizumab." @default.
• W2613767797 created "2017-05-19" @default.
• W2613767797 creator A5001471700 @default.
• W2613767797 creator A5013879260 @default.
• W2613767797 creator A5023350155 @default.
• W2613767797 creator A5028081204 @default.
• W2613767797 creator A5056674765 @default.
• W2613767797 creator A5066028226 @default.
• W2613767797 date "2017-05-10" @default.
• W2613767797 modified "2023-10-12" @default.
• W2613767797 title "Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France" @default.
• W2613767797 cites W170558594 @default.
• W2613767797 cites W1935664893 @default.
• W2613767797 cites W1966486839 @default.
• W2613767797 cites W1971066434 @default.
• W2613767797 cites W1984047598 @default.
• W2613767797 cites W1987334421 @default.
• W2613767797 cites W1988218552 @default.
• W2613767797 cites W2019553690 @default.
• W2613767797 cites W2035679927 @default.
• W2613767797 cites W2039482367 @default.
• W2613767797 cites W2045275571 @default.
• W2613767797 cites W2056293400 @default.
• W2613767797 cites W2064133515 @default.
• W2613767797 cites W2068742492 @default.
• W2613767797 cites W2069002125 @default.
• W2613767797 cites W2070175039 @default.
• W2613767797 cites W2075984382 @default.
• W2613767797 cites W2080886828 @default.
• W2613767797 cites W2088353193 @default.
• W2613767797 cites W2092201615 @default.
• W2613767797 cites W2092858963 @default.
• W2613767797 cites W2099511225 @default.
• W2613767797 cites W2113854172 @default.
• W2613767797 cites W2122178465 @default.
• W2613767797 cites W2124415048 @default.
• W2613767797 cites W2127980999 @default.
• W2613767797 cites W2164434374 @default.
• W2613767797 cites W2164644059 @default.
• W2613767797 cites W2167993599 @default.
• W2613767797 cites W2170700627 @default.
• W2613767797 cites W2321951184 @default.
• W2613767797 cites W2407900407 @default.
• W2613767797 cites W3033148357 @default.
• W2613767797 cites W4239413292 @default.
• W2613767797 cites W2396333249 @default.
• W2613767797 doi "https://doi.org/10.1007/s00417-017-3685-y" @default.
• W2613767797 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5541092" @default.
• W2613767797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28493086" @default.
• W2613767797 hasPublicationYear "2017" @default.
• W2613767797 type Work @default.
• W2613767797 sameAs 2613767797 @default.
• W2613767797 citedByCount "19" @default.
• W2613767797 countsByYear W26137677972017 @default.
• W2613767797 countsByYear W26137677972018 @default.
• W2613767797 countsByYear W26137677972019 @default.
• W2613767797 countsByYear W26137677972020 @default.
• W2613767797 countsByYear W26137677972021 @default.
• W2613767797 countsByYear W26137677972022 @default.
• W2613767797 countsByYear W26137677972023 @default.
• W2613767797 crossrefType "journal-article" @default.
• W2613767797 hasAuthorship W2613767797A5001471700 @default.
• W2613767797 hasAuthorship W2613767797A5013879260 @default.
• W2613767797 hasAuthorship W2613767797A5023350155 @default.
• W2613767797 hasAuthorship W2613767797A5028081204 @default.
• W2613767797 hasAuthorship W2613767797A5056674765 @default.
• W2613767797 hasAuthorship W2613767797A5066028226 @default.
• W2613767797 hasBestOaLocation W26137677971 @default.
• W2613767797 hasConcept C118487528 @default.
• W2613767797 hasConcept C126322002 @default.
• W2613767797 hasConcept C134018914 @default.
• W2613767797 hasConcept C141071460 @default.
• W2613767797 hasConcept C16005928 @default.
• W2613767797 hasConcept C167135981 @default.
• W2613767797 hasConcept C188816634 @default.
• W2613767797 hasConcept C195910791 @default.
• W2613767797 hasConcept C2776694085 @default.
• W2613767797 hasConcept C2777802072 @default.
• W2613767797 hasConcept C2778028898 @default.
• W2613767797 hasConcept C2778257484 @default.
• W2613767797 hasConcept C2778784831 @default.
• W2613767797 hasConcept C2779829184 @default.
• W2613767797 hasConcept C2781100027 @default.
• W2613767797 hasConcept C2781359195 @default.
• W2613767797 hasConcept C555293320 @default.
• W2613767797 hasConcept C71924100 @default.
• W2613767797 hasConcept C72563966 @default.
• W2613767797 hasConceptScore W2613767797C118487528 @default.
• W2613767797 hasConceptScore W2613767797C126322002 @default.
• W2613767797 hasConceptScore W2613767797C134018914 @default.
• W2613767797 hasConceptScore W2613767797C141071460 @default.
• W2613767797 hasConceptScore W2613767797C16005928 @default.
• W2613767797 hasConceptScore W2613767797C167135981 @default.
• W2613767797 hasConceptScore W2613767797C188816634 @default.
• W2613767797 hasConceptScore W2613767797C195910791 @default.
• W2613767797 hasConceptScore W2613767797C2776694085 @default.
• W2613767797 hasConceptScore W2613767797C2777802072 @default.
• W2613767797 hasConceptScore W2613767797C2778028898 @default.

• next